科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一,在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业,通过齐心协力确保高品质治疗与成功康复。

医疗程序操作医生

显示 1-3 名医生(共 3 名医生)可选

姓氏首字母: H

  1. Shahrukh K. Hashmi, M.D.

    Shahrukh K. Hashmi, M.D.

    1. Hematologist
    2. Public Health and General Preventive Medicine Specialist
    1. Rochester, MN
    擅长领域:

    Bone marrow transplant, Myelodysplastic syndromes, Graft versus host disease, Acute leukemia

  2. Walter C. Hellinger, M.D.

    Walter C. Hellinger, M.D.

    1. Internist
    2. Infectious Disease Specialist
    擅长领域:

    Infection control, Bone marrow transplant, Transplant, Infection, General infectious diseases

  3. William J. Hogan, M.B., B.Ch.

    William J. Hogan, M.B., B.Ch.

    1. Internist
    2. Hematologist
    3. Oncologist
    1. Rochester, MN
    擅长领域:

    Autologous stem cell transplant, Allogeneic stem cell transplant, Bone marrow transplant, Acute leukemia, Myeloprolifer...ative disorders, Chronic myelomonocytic leukemia, Acute myelogenous leukemia, Chronic myelogenous leukemia, Myelofibrosis, Aplastic anemia, Leukemia, Myelodysplastic syndromes, Acute lymphocytic leukemia

研究

妙佑医疗国际的医生和科学家们正在积极研究改善骨髓移植预后的相关方法。研究领域包括:

  • 扩展单倍体相合骨髓移植的应用
  • 寻找骨髓移植的新方法,包括小儿血红蛋白病和遗传性代谢病
  • 改善骨髓移植幸存者的生活质量
  • 预防和应对移植物抗宿主病 (GVHD)
  • 了解慢性移植物抗宿主病 (GVHD)

了解更多关于骨髓移植计划的相关研究。

妙佑医疗国际癌症中心和其他机构合作进行癌症研究。妙佑医疗国际癌症中心接受美国国家癌症研究所的资助,是美国指定的综合性癌症中心,这是对机构专注癌症预防、诊断和治疗的科学性卓越成就和多学科资源的认可。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在骨髓移植领域的文献著述列表

Research Profiles

在 Mayo Clinic 治疗

Jan. 13, 2022
  1. AskMayoExpert. Hematopoietic stem cell transplant. Mayo Clinic; 2019.
  2. Hoffman R, et al. Overview of hematopoietic stem cell transplantation. In: Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed July 8, 2016.
  3. Blood-forming stem cell transplants. National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. Accessed July 8, 2016.
  4. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2012;18:348.
  5. Diseases treatable by transplants. National Marrow Donor Program. https://bethematch.org/transplant-basics/how-transplants-work/diseases-treatable-by-transplants/. Accessed Aug. 1, 2019.
  6. AskMayoExpert. Graft-versus-host disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  7. Blood and marrow stem cell transplantation. Leukemia & Lymphoma Society. https://www.lls.org/resource-center/download-or-order-free-publications. Accessed Aug. 1, 2019.
  8. Barbara Woodward Lips Patient Education Center. Autologous stem cell transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  9. Blood and bone marrow transplant. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/blood-and-bone-marrow-transplant. Accessed Aug. 13, 2019.
  10. D'Souza A, et al. Current use and trends in hematopoietic cell transplantation in the United States. Biology of Blood and Marrow Transplantation. 2017; doi:10.1016/j.bbmt.2017.05.035.
  11. Jagasia MH, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation. 2015; doi:10.1016/j.bbmt.2014.12.001.
  12. Blood and marrow transplant (BMT): An introduction to allogeneic BMT. Leukemia & Lymphoma Society. https://www.lls.org/resource-center/download-or-order-free-publications. Accessed Aug. 1, 2019.
  13. Majhail NS. Long term complications after hematopoietic cell transplantation. Hematology Oncology Stem Cell Therapy. 2017; doi:10.1016/j.hemonc.2017.05.009.
  14. Hashmi SK, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group report. Biology of Blood and Marrow Transplantation. 2017; doi:10.1016/j.bbmt.2016.09.025.
  15. DeFilipp Z, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: Screening and preventive practice recommendations from CIBMTR and EBMT. Biology of Blood and Marrow Transplantation. 2016; doi:10.1038/bmt.2016.203.
  16. Mills SD, et al. Bone-marrow transplant in an identical twin. JAMA. 1964; doi:10.1001/jama.1964.03060380005001.
  17. Rashidi A, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances. 2019; doi:10.1182/bloodadvances.2019000050.
  18. Ahmed S, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 2019; doi:10.1016/j.bbmt.2019.05.025.
  19. Jain T, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: A systematic review and meta-analysis. Biology of Blood and Marrow Transplantation. 2019; doi:10.1016/j.bbmt.2018.11.016.
  20. Chen YB, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Advances. 2019; doi:10.1182/bloodadvances.2018027599.
  21. Ballen KK, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: Comparison among alternative graft sources. Biology of Blood and Marrow Transplantation. 2014; doi:10.1016/j.bbmt.2014.07.021.
  22. Sweeney SK, et al. Tracking embryonic hematopoietic stem cells to the bone marrow: Nanoparticle options to evaluate transplantation efficiency. Stem Cell Research & Therapy. 2018; doi:10.1186/s13287-018-0944-8.
  23. Kumar A, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis: An updated systematic review and meta-analysis. Bone Marrow Transplantation. 2019; doi:10.1038/s41409-018-0393-0.
  24. Graff TM, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015; doi: 10.1038/bmt.2015.46.
  25. Brown AY. Allscripts EPSi. Mayo Clinic. Sept. 16, 2019.
  26. Search for a FACT accredited organization. Foundation for the Accreditation of Cellular Therapy (FACT). http://accredited.factwebsite.org/. Accessed Aug. 13, 2019.
  27. Transplant center search results. Be The Match. https://bethematch.org/tcdirectory/search/advanced/#mayo/-/-/false/-.Accessed Aug. 13, 2019.
  28. Participating transplant centers. Center for International Blood and Marrow Transplant Research. https://www.cibmtr.org/About/WhoWeAre/Centers/Pages/index.aspx?country=us&state=Minnesota. Accessed Aug. 13, 2019.
  29. Locations. Children's Oncology Group. https://childrensoncologygroup.org/index.php/locations/. Accessed Aug. 13, 2019.
  30. Participating institutions. ECOG-ACRIN Cancer Research Group. https://ecog-acrin.org/participating-institutions. Accessed Aug. 13, 2019.
  31. PBMTC members. Pediatric Blood and Marrow Transplant Consortium. http://www.pbmtc.org/about/members/full. Accessed Aug. 13, 2019.
  32. Participating clinical centers. Primary Immune Deficiency Treatment Consortium. https://www.rarediseasesnetwork.org/cms/pidtc/Learn-More/Participating-Clinical-Centers. Accessed Aug. 13, 2019.

相关

产品与服务